Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma

Journal of the American Academy of Dermatology

Volumn 47, Issue 6, 2002, Pages 956-961

  Shapiro, Michael ^a   Rook, Alain H ^a   Lehrer, Michael S ^a   Junkins Hopkins, Jacqueline M ^a   French, Lars E ^b   Vittorio, Carmela C ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c Rhoads Pavilion   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEXAROTENE; BIOLOGICAL RESPONSE MODIFIER; CHLORMETHINE; ETRETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PSORALEN; RETINOID; RETINOID X RECEPTOR; STEROID;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CUTANEOUS T CELL LYMPHOMA; FLOW CYTOMETRY; HELPER CELL; HUMAN; IMMUNE RESPONSE; MALE; MALIGNANT TRANSFORMATION; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PUVA; SKIN BIOPSY; T CELL LYMPHOMA; ULTRAVIOLET A RADIATION;

EID: 0036896516     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.124816     Document Type: Article

References (50)

1. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sézary syndrome patients: Cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-4.
2. Vowels BR, Lessin SR,Cassin M,Jaworsky C, Benoit B, Wolfe JT, et al. Th2 cytokine mRNA expression in skin in cutaneous T cell lymphoma. J Invest Dermatol 1994;103:669-73.
3. Rook AH, Heald P.The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:997-1010.
4. Dummer R, Heald PW, Nestle FO, Ludwig E,Laine E, Hemmi S, et al. Sézary syndrome T cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta chain). Blood 1996;88:1383.
5. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10. J Invest Dermatol 1996;107:833.
6. Rook AH, Kubin M, Cassin M, Vonderheid EC, Vowels BR, Wolfe JT, et al. IL-12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995;154:1491-8.
7. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.
8. Berger C, Liu W, Heald P, Christensen I, Edelson R. Antitumor response in cutaneous T-cell lymphoma [abstract]. J Invest Dermatol 1994;102:556.
9. Kim YH, Jensen RA, Watanabe GL, Varhese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. Arch Dermatol 1996;132:1309-13.
10. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, et al. Histologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.
11. Kim YH, Hoppe RT. Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999;26:276-89.
12. Foss FM, Sausville EA. Prognosis and staging of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1011-9.
13. Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapies of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121:592-602.
14. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
15. Gottlieb SL, Wolfe JT, Fox FE, DeNardo BJ, Macey WH, Bromley PG, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis and in combination with recombinant interferon alfa: A 10-year experience at a single institution. J Am Acad Dermatol 1996;35:946-57.
16. Rook AH, Suchin KR, Kao DMF, Yoo EK, Macey WH, DeNardo BJ, et al. Photopheresis: Clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999;4:85-90.
17. Knobler RM, Trautinger F, Radaszkiewicz T. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991;24:247-52.
18. Dreno B, Celorier P, Litoux P. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993;89(Suppl 1):28-32.
19. Dreno B. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993;11:269-75.
20. Stadler R, Otte HG, Luger T, Henz BM, Kühl P, Zwingers T, et al. Prospective randomized multicentre clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578-81.
21. Kuzel TM, Roenigk HH Jr, Samuelson E, Herrmann JJ, Huria A, Rademaker AW, et al. Effectiveness of interferon alfa-2a combined with photochemotherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995;13:257.
22. Dreno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low dose interferon alfa-2a alone and etretinate. Br J Dermatol 1991;125:456.
23. Thestrup-Pedersen K, Hammer R, Kaltoft K, Sogard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon alpha-2a alone and in combination with etretinate. Br J Dermatol 1988;118:811.
24. Altomare GF, Capella GI, Pigatto PD, Finzi AF. Intramuscular low dose alpha-2b interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993;32:138.
25. Stavrianeas N, Katsambas A, Vareltzides A, Stavropoulos P, Polydorou D, Zika P, et al. Treatment of mycosis fungoides with recombinant alpha 2b interferon in combination with etretinate. J Invest Dermatol 1989;93:850.
26. Braathen LS, McFadden N. Successful treatment of mycosis fungoides with the combination of etretinate and human recombnant interferon alfa-2a. J Dermatol Treat 1989;1:29.
27. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol (Stockh) 1989;69:536-8.
28. Serri F, De Simone C, Venier A, Rusciani L, Marchetti F. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Curr Probl Dermatol 1990;19:252-7.
29. Kessler JF, Jones SE, Levine N. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.
30. Thomsen K, Molin L, Volden G. 13-Cis retinoic acid effective in mycosis fungoides. Acta Derm Venereol (Stockh) 1984;64:563-6.
31. Majewski S, Szmurlo A, Marczak S, Jablonska S, Bollag W. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect of HPV-harboring tumor-cell lines. Int J Cancer 1994;57:81-5.
32. Lancilloti F, Giandomenico E, Affabris G, Fiorucci G, Romeo G, Rossi GB. Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells. Cancer Res 1995; 55:3158-64.
33. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. Structurally similar but functionally distinct factors, IRF1 and IRF2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 1989;58:729-39.
34. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, et al. Antioncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993;259:971-4.
35. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF1. Cell 1994;77:829-39.
36. Boehm MF, Zhang L, Badea B, White SK, Mais DE, Berger E, et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930-41.
37. Dong D, Noy N. Heterodimer formation by retinoid X receptor: Regulation by ligands and by the receptor's self-association properties. Biochemistry 1998;37:10691-700.
38. Mehta K, McQueen T, Neamati N, Collins S, Andreeff M. Activation of retinoid receptors RAR-a and RXR-a induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1996;7:179-86.
39. Nagy L, Thomazy VA, Shipley GL, Fesus L, Lamph W, Heyman RA, et al. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol 1995;15:3540-51.
40. Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): An RXR-selective ligand. Cancer Res 1996;56:5566-70.
41. Kizaki M, Dawson MI, Heyman R, Elster E, Morosetti R, Pakkala S, et al. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro. Blood 1996;87:1977-84.
42. Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997;57:2642-50.
43. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: The retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998;58:479-84.
44. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997;15:790-5.
45. Duvic M, Martin A, Kim Y, Olsen E, Wood G, Yocum R, et al. Oral bexarotene is safe and effective in a phase II-III clinical trial in refractory or persistent early stage CTCL. Blood 1999;94(Suppl 1 part 1):659a.
46. Hymes K, Duvic M, Heald P, Breneman D, Martin A, Myskowski P, et al. Oral bexarotene benefits patients with refractory advanced stage CTCL. Blood 1999;94(Suppl 1 part 1)97a.
47. Krust A, Kastner P, Petkovich M, Zelent A, Chambon P. A third human retinoic acid receptor, hRAR-γ. Proc Natl Acad Sci U S A 1989;86:5310-4.
48. Zelent A, Krust A, Petkovich M, Kastner P, Chambon P. Cloning of a murine α and β retinoic acid receptors and a novel receptor γ predominantly expressed in skin. Nature 1989;339:714-7.
49. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075-9.
50. Anonymous. Bexarotene (Targretin) for cutaneous T-cell lymphoma. Med Lett Drugs Ther 2000;42:31-2.